About admin

This author has not yet filled in any details.
So far admin has created 35 blog entries.

Årsredovisning 2015

By |2018-11-20T23:59:31+00:00November 19th, 2018|

Årsredovisning 2015 Contact information Full Company Name:   Double Bond Pharmaceutical International AB (publ) Corporate identity:       556991-6082 Stock short name:       DBP B Share ISIN code:         SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]

Clinical trial of Inofer: half of the patients already recruited

By |2018-11-20T22:07:49+00:00November 19th, 2018|

Clinical trial of Inofer: half of the patients already recruited WED, NOV 14, 2018 08:00 CET The tenth patient of twenty has now been recruited for the clinical study of the iron tablets Inofer, which Drugsson AB (subsidiary of Double Bond Pharmaceutical) has the rights [...]

DBP gets free Protocol Assistance from EMA for SI-053

By |2018-11-20T22:04:54+00:00November 19th, 2018|

DBP gets free Protocol Assistance from EMA for SI-053 TUE, NOV 06, 2018 08:13 CET Double Bond Pharmaceutical has submitted an application to EMA for scientific advice, known as Protocol Assistance, for SI-053. The assistance will be given during a pre-submission meeting, where DBP is [...]

Clinical trial of Inofer has started

By |2018-11-20T22:27:53+00:00November 19th, 2018|

Clinical trial of Inofer has started FRI, OCT 05, 2018 08:45 CET The clinical study for the iron tablets Inofer, which Drugsson AB (subsidiary of Double Bond Pharmaceutical) has the rights for in Sweden, Norway, Denmark and Finland has now begun. A clinical trial of [...]

The preclinical development program of SI-053 is complete

By |2018-11-20T22:32:59+00:00November 19th, 2018|

The preclinical development program of SI-053 is complete THU, OCT 04, 2018 08:43 CET The results of the two remaining preclinical studies are now available. The toxicological studies on SI053 and its formulation showed expected results. The study on the excipient was a long-term study [...]

Double Bond Pharmaceutical about to sell Temodex in Latin America

By |2018-11-20T22:36:36+00:00November 19th, 2018|

Double Bond Pharmaceutical about to sell Temodex in Latin America FRI, SEP 28, 2018 08:09 CET Double Bond Pharmaceutical and CLOSTER PHARMA S.A.S (Colombia) have signed a distribution agreement for Temodex in Mexico, Brazil, Colombia, Peru, Ecuador and Costa Rica. The distribution will be carried [...]

The new issue of shares in FarmPharma via FundedByMe is closed

By |2018-11-20T22:40:59+00:00November 19th, 2018|

The new issue of shares in FarmPharma via FundedByMe is closed WED, SEP 26, 2018 08:58 CET Today, 26 september the Board of FarmPharma AB, a wholly-owned subsidiary of Double Bond Pharmaceutical, has closed the new issue via FundedByMe. 83 investors participated in the rights [...]

Article about MGMT study accepted for publication in Neoplasma

By |2018-11-20T22:45:01+00:00November 19th, 2018|

Article about MGMT study accepted for publication in Neoplasma TUE, SEP 25, 2018 08:17 CET A scientific article on Double Bond Pharmaceutical's investigation into how MGMT status affects the effectiveness of treatment with Temodex has been accepted for publication in the journal Neoplasma. "The information [...]